| Literature DB >> 33654738 |
Nancy Meyer1,2, Omar Davulcu1,3, Qing Xie1,4, Mark Silveria5, Grant M Zane5, Edward Large5, Michael S Chapman1,5.
Abstract
Adeno-associated virus (AAV) is a promising gene therapy vector and the biophysical characterization of its interactions with host proteins is a critical foundation for engineering tissue targeting and immune escape. Presented here are protocols for the production of: (a) the outer protein shells (virus-like particles or VLPs) for serotype 2 (AAV-2) and (b) two fragments from the binding ectodomain of AAV's cellular receptor, AAVR. His6PKD1-2 comprises the first two polycystic kidney disease (PKD) domains, the minimal required for efficient binding of AAV, expressed with an N-terminal histidine tag. MBP-PKD1-5 is a fusion of the maltose binding protein with all five of the PKD domains of the AAVR receptor. Presented are the expression and purification of milligram quantities, ample for in vitro analyses. For AAV-2, the protocol offers an alternative to the use of (infectious) wild-type virus or transducing vectors. One of the methods for producing transducing vector is in Sf9 cells, and the production of VLPs is based on this. For AAVR, the protocols enable biochemical and biophysical characterization of virus-binding. The minimal two-domain construct allows more saturated binding to symmetry-equivalent sites on the virus, while the larger construct might be better expected to reflect the native receptor.Entities:
Keywords: AAV; AAVR; Adeno-associated virus; Co-receptor; Gene therapy; Viral entry; Virus; Virus receptor
Year: 2020 PMID: 33654738 PMCID: PMC7842819 DOI: 10.21769/BioProtoc.3513
Source DB: PubMed Journal: Bio Protoc ISSN: 2331-8325